Zacks: Brokerages Anticipate Microbot Medical Inc. (NASDAQ:MBOT) to Announce -$0.42 Earnings Per Share

Wall Street brokerages expect that Microbot Medical Inc. (NASDAQ:MBOTGet Rating) will post earnings per share of ($0.42) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Microbot Medical’s earnings. Microbot Medical reported earnings per share of ($0.34) in the same quarter last year, which suggests a negative year over year growth rate of 23.5%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Microbot Medical will report full-year earnings of ($1.62) per share for the current year. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Microbot Medical.

Separately, Zacks Investment Research upgraded Microbot Medical from a “sell” rating to a “hold” rating in a research report on Thursday, April 7th.

NASDAQ MBOT traded up $0.05 during trading hours on Thursday, reaching $6.20. 13,245 shares of the stock traded hands, compared to its average volume of 129,237. The stock has a 50 day simple moving average of $5.71 and a two-hundred day simple moving average of $6.14. Microbot Medical has a 1 year low of $4.31 and a 1 year high of $9.60. The company has a market cap of $44.07 million, a price-to-earnings ratio of -4.37 and a beta of 4.23.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MBOT. Morgan Stanley grew its stake in shares of Microbot Medical by 74.2% in the second quarter. Morgan Stanley now owns 3,504 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,492 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Microbot Medical in the fourth quarter worth about $77,000. Virtu Financial LLC bought a new stake in shares of Microbot Medical in the fourth quarter worth about $95,000. Dimensional Fund Advisors LP grew its stake in shares of Microbot Medical by 78.1% in the third quarter. Dimensional Fund Advisors LP now owns 95,064 shares of the biotechnology company’s stock worth $668,000 after purchasing an additional 41,686 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new stake in shares of Microbot Medical in the fourth quarter worth about $750,000. Hedge funds and other institutional investors own 9.54% of the company’s stock.

Microbot Medical Company Profile (Get Rating)

Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature.

Recommended Stories

Get a free copy of the Zacks research report on Microbot Medical (MBOT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.